Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to CobenfyTM (xanomeline and trospium chloride)

AI Briefing

• – Cobenfy, an oral combination of xanomeline and trospium chloride, demonstrates symptom stability when transitioning from oral atypical antipsychotics.
• – The study shows no significant change in symptoms in patients undergoing the switch from oral atypical antipsychotics to Cobenfy.
• – The results suggest that Cobenfy may be a viable treatment option for patients who have not responded to or cannot tolerate oral atypical antipsychotics.